Caldera Therapeutics (Series A and Series A-1)
Funding Details
Awarder
RSS - feeds.feedburner.com
Date Award
January 16, 2026
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount
$112,500,000
Company Info
Traction
First subjects have been dosed in the Phase 1 trial of its lead program, CLD-423.
Market
Inflammatory bowel disease and other immunologic and inflammatory diseases
Location
Cambridge, MA, USA
Coinvestors
Atlas Venture, LAV, venBio, Omega Funds, Wellington Management, Janus Henderson Investors
Company Description

Caldera, a clinical stage biotechnology company developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.

Links
Website
Back to HomeBack to Biotechnology DealsView Funding Announcement